A new treatment for men with prostate cancer
Part of Cancer clinical trials.
This trial tests an investigational drug called DKF-MA102 for men with prostate cancer. The study aims to see if this drug can help control the cancer while keeping testosterone levels within a certain range.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 19 or older.
- You have been diagnosed with prostate cancer (confirmed by a biopsy or other lab test).
- Your testosterone level is above 150 ng/dL.
- You are able to do your daily activities with little or no help (ECOG score 0 to 2).
- You are expected to live at least one more year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new targeted therapy (DEC003M) for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to see if this treatment is safe and helps shrink tumors.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests a new drug, GSK5458514, either alone or with other cancer treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if the drug can slow down the cancer.
This early-phase trial tests a new oral drug, GT-220F, for men whose prostate cancer has spread and no longer responds to hormone therapy. It may be especially for patients whose cancer has specific genetic changes in the PTEN or PIK3CB genes.
Hear when a new Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.